[HIGHLIGHTS] Green light for bronchiolitis virus vaccine that kills thousands of people a year

The European Commission has authorized the sale of the Arexvy vaccine against respiratory syncytial virus (RSV) The vaccine had already received a first marketing authorization on May 3, 2023 in the United States. Each year, the virus generates in Europe "more than 270,000 hospitalizations and about 20,000 deaths during hospitalization" in older people.Having had RSV bronchiolitis before age 3 could increase asthma risk by 2.5%.

The European Medicines Agency (EMA) was in favour of authorisation last month.